NovoCure Limited (NASDAQ:NVCR) went up by 6.25% from its latest closing price compared to the recent 1-year high of $232.76. The company’s stock price has collected 0.54% of gains in the last five trading sessions. Press Release reported on 01/10/22 that Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
Is It Worth Investing in NovoCure Limited (NASDAQ :NVCR) Right Now?
Plus, the 36-month beta value for NVCR is at 0.92.
NVCR currently public float of 89.97M and currently shorts hold a 6.45% ratio of that float. Today, the average trading volume of NVCR was 655.53K shares.
NVCR’s Market Performance
NVCR stocks went up by 0.54% for the week, with a monthly drop of -16.11% and a quarterly performance of -34.90%, while its annual performance rate touched -58.95%. The volatility ratio for the week stands at 6.57% while the volatility levels for the past 30 days are set at 6.15% for NovoCure Limited. The simple moving average for the period of the last 20 days is -6.90% for NVCR stocks with a simple moving average of -50.09% for the last 200 days.
Analysts’ Opinion of NVCR
Many brokerage firms have already submitted their reports for NVCR stocks, with Evercore ISI repeating the rating for NVCR by listing it as a “In-line.” The predicted price for NVCR in the upcoming period, according to Evercore ISI is $82 based on the research report published on January 03rd of the current year 2022.
Wedbush gave a rating of “Underperform” to NVCR, setting the target price at $154 in the report published on April 14th of the previous year.
NVCR Trading at -20.24% from the 50-Day Moving Average
After a stumble in the market that brought NVCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.79% of loss for the given period.
Volatility was left at 6.15%, however, over the last 30 days, the volatility rate increased by 6.57%, as shares sank -12.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.72% lower at present.
During the last 5 trading sessions, NVCR rose by +0.54%, which changed the moving average for the period of 200-days by -42.00% in comparison to the 20-day moving average, which settled at $77.49. In addition, NovoCure Limited saw -3.25% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NVCR starting from Burke William Patrick, who sale 3,951 shares at the price of $76.00 back on Jan 03. After this action, Burke William Patrick now owns 41,036 shares of NovoCure Limited, valued at $300,263 using the latest closing price.
Danziger Asaf, the Chief Executive Officer of NovoCure Limited, purchase 4,974 shares at $102.44 during a trade that took place back on Nov 26, which means that Danziger Asaf is holding 13,276 shares at $509,539 based on the most recent closing price.
Stock Fundamentals for NVCR
Current profitability levels for the company are sitting at:
- +6.23 for the present operating margin
- +78.54 for the gross margin
The net margin for NovoCure Limited stands at +4.01. The total capital return value is set at 4.69, while invested capital returns managed to touch 3.04. Equity return is now at value -6.50, with -2.50 for asset returns.
Based on NovoCure Limited (NVCR), the company’s capital structure generated 94.58 points at debt to equity in total, while total debt to capital is 48.61. Total debt to assets is 42.84, with long-term debt to equity ratio resting at 93.22. Finally, the long-term debt to capital ratio is 47.91.
When we switch over and look at the enterprise to sales, we see a ratio of 37.29, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 6.01 and the total asset turnover is 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.80.